National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C

JAMA  Published Online: March 25, 2026 
Sanjay Kishore, MD1; Margaret Hayden, MD, MPhil1; Micah Johnson, MD2

Since initially becoming available in 2013, direct-acting antivirals (DAAs) have transformed the treatment of hepatitis C virus (HCV) infection. Treatment is well tolerated and results in cure (sustained virologic response) in more than 95% of individuals. However, only about a third of people in the US with HCV infection receive treatment within a year of diagnosis, an estimated 2.5 million to 4 million remain chronically infected, and incident cases of HCV have increased during the last decade.1,2 To better understand how the use of DAAs has evolved in the US, this study measured changes in patient and prescriber characteristics for these medications from 2013 to 2025.

TO READ FULL ARTICLE:https://jamanetwork.com/journals/jama/fullarticle/2846850​